{"entity":{"id":"nct03828227","kind":"trial","name":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","aka":["COLAGE"],"tldr":"A phase 3 trial of capecitabine and bevacizumab (glioblastoma use) in colorectal cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, active but no longer recruiting.","summary":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. is a phase 3, randomised interventional study registered as NCT03828227 by GERCOR - Multidisciplinary Oncology Cooperative Group, with a registry enrolment figure of 49 participants, started 2019-06-14 and due to reach its primary completion in 2023-11-10. Interventions recorded: OPTIMOX-bevacizumab; Capecitabine plus bevacizumab. Conditions listed: Elderly Patients; Metastatic Colorectal Cancer; Quality of Life. Primary outcome: Health-related quality of life (HRQoL) at 6 months in the \"candidate group\".. Colorectal eligibility wording from the registry: \"Histologically proven colorectal adenocarcinoma,\". Sites: France. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03828227","url":"https://clinicaltrials.gov/study/NCT03828227"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["capecitabine","bevacizumab-glioma"],"companies":["gercor"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03828227","phase":"3","setting":"Phase III Study to Evaluate the Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters.","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","participation":[{"nct":"NCT03828227","source":"https://clinicaltrials.gov/study/NCT03828227","fetchedAt":"2026-10-07T16:53:09.552Z","studySha256":"be1bce00a57bdd09b5d0ca502b41dfea926a3ca95531c9ba10f5ada339731d71","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-07-18","leadSponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","collaboratorCount":0,"minimumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":49,"enrolmentType":"ACTUAL","siteCount":22,"recruitingSiteCount":0,"countries":["France"]}],"started":"2019-06-14","startedType":"actual","enrolled":49,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03828227/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}],"company":[{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}